TYRO3 and ovarian cancer: Thus, these data show that metformin can sensitize cisplatin/taxol-resistant ovarian cancer cells to these drugs, reducing AXL and TYRO3 RTK expression and favoring apoptosis [53] suggesting a potential use of metformin as anticancer compound alone or in combination with other molecules to target different cell pathways [54,55].